Manuel Battegay Div. Infectious Diseases & Hospital Epidemiology HIV complications and morbidity.
Capital efficiency and maximising returns on capital/embedded value
NVAC H1N1 Vaccine Safety Risk Assessment Working Group (VSRAWG) Update NVAC Meeting June 2, 2010 Marie McCormick, M.D., Sc.D. Sumner and Esther Feldberg.
NVAC H1N1 Vaccine Safety Risk Assessment Working Group (VSRAWG) Update
1 Pneumococcal 13-valent Conjugate Vaccine Post Licensure Pharmacovigilance and Vaccine Effectiveness Plans Robert Wise, MD, MPH Marthe Bryant-Genevier,
Encuesta de percepcion en seguridad en los pasies de la UE
